Updates on sphingolipids: Spotlight on retinopathy

The sphingolipids ceramide (Cer), ceramide-1-phosphate (C1P), sphingosine (Sph), and sphingosine-1-phosphate (S1P)) are key signaling molecules that regulate many patho-biological processes. During the last decade, they have gained increasing attention since they may participate in important and num...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2021-11, Vol.143, p.112197-112197, Article 112197
Hauptverfasser: Shiwani, Haaris A., Elfaki, Mohammed Y., Memon, Danyal, Ali, Suhayb, Aziz, Abdul, Egom, Emmanuel E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 112197
container_issue
container_start_page 112197
container_title Biomedicine & pharmacotherapy
container_volume 143
creator Shiwani, Haaris A.
Elfaki, Mohammed Y.
Memon, Danyal
Ali, Suhayb
Aziz, Abdul
Egom, Emmanuel E.
description The sphingolipids ceramide (Cer), ceramide-1-phosphate (C1P), sphingosine (Sph), and sphingosine-1-phosphate (S1P)) are key signaling molecules that regulate many patho-biological processes. During the last decade, they have gained increasing attention since they may participate in important and numerous retinal processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Cer for instance has emerged as a key mediator of inflammation and death of neuronal and retinal pigment epithelium cells in experimental models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. S1P may have opposite biological actions, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1- phosphate may also contribute to uveitis. Furthermore, use of inhibitors that either prevent Cer increase or modulate S1P signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), have been shown to preserve neuronal viability and retinal function. Collectively, the expanding role for these sphingolipids in the modulation of vital processes in retina cell types and in their dysregulation in retinal degenerations makes them attractive therapeutic targets. •Sphingolipids are a class of diverse molecules with differing structure and function.•Cer and Sph are sphingolipids which are involved with cell death and apoptosis.•S1P and C1P are sphingolipids involved with cell proliferation.•Sphingolipid targeted drugs may be novel therapeutic options for retinopathic disease.
doi_str_mv 10.1016/j.biopha.2021.112197
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2576652386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332221009811</els_id><sourcerecordid>2576652386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-3a7c7bf7d0787d73c21d9956cfa0da061c239de60970e7236e2eff3ab1ae6b163</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EoqXwDxDqyJJwthM7YUBCFV9SJQbobDn2pXGVxiFOkfrvaZTCyHTDPe-9uoeQawoxBSruNnHhfFvpmAGjMaWM5vKETGmeQiQA5CmZgkx5xDljE3IRwgYAUsGzczLhSSogTeiUsFVrdY9h7pt5aCvXrH3tWmfD_fyj9X3t1lU_7DrsXeNb3Vf7S3JW6jrg1XHOyOr56XPxGi3fX94Wj8vIJJD1EdfSyKKUFmQmreSGUZvnqTClBqtBUMN4blFALgEl4wIZliXXBdUoCir4jNyOd9vOf-0w9GrrgsG61g36XVAslUKkjGcDmoyo6XwIHZaq7dxWd3tFQQ221EaNttRgS422DrGbY8Ou2KL9C_3qOQAPI4CHP78ddioYh41B6zo0vbLe_d_wAxrofF4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576652386</pqid></control><display><type>article</type><title>Updates on sphingolipids: Spotlight on retinopathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Shiwani, Haaris A. ; Elfaki, Mohammed Y. ; Memon, Danyal ; Ali, Suhayb ; Aziz, Abdul ; Egom, Emmanuel E.</creator><creatorcontrib>Shiwani, Haaris A. ; Elfaki, Mohammed Y. ; Memon, Danyal ; Ali, Suhayb ; Aziz, Abdul ; Egom, Emmanuel E.</creatorcontrib><description>The sphingolipids ceramide (Cer), ceramide-1-phosphate (C1P), sphingosine (Sph), and sphingosine-1-phosphate (S1P)) are key signaling molecules that regulate many patho-biological processes. During the last decade, they have gained increasing attention since they may participate in important and numerous retinal processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Cer for instance has emerged as a key mediator of inflammation and death of neuronal and retinal pigment epithelium cells in experimental models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. S1P may have opposite biological actions, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1- phosphate may also contribute to uveitis. Furthermore, use of inhibitors that either prevent Cer increase or modulate S1P signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), have been shown to preserve neuronal viability and retinal function. Collectively, the expanding role for these sphingolipids in the modulation of vital processes in retina cell types and in their dysregulation in retinal degenerations makes them attractive therapeutic targets. •Sphingolipids are a class of diverse molecules with differing structure and function.•Cer and Sph are sphingolipids which are involved with cell death and apoptosis.•S1P and C1P are sphingolipids involved with cell proliferation.•Sphingolipid targeted drugs may be novel therapeutic options for retinopathic disease.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2021.112197</identifier><identifier>PMID: 34560541</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Age-related macular degeneration ; Animals ; Ceramide ; Ceramide-1-phosphate ; Ceramides - metabolism ; Fingolimod Hydrochloride - therapeutic use ; Humans ; Lysophospholipids - metabolism ; Molecular Targeted Therapy ; Photoreceptor ; Photoreceptor Cells, Vertebrate - metabolism ; Retina - drug effects ; Retina - metabolism ; Retina - pathology ; Retinal Diseases - drug therapy ; Retinal Diseases - metabolism ; Retinal Diseases - pathology ; Retinal Ganglion Cells - metabolism ; Retinal pigment epithelium ; Retinal Pigment Epithelium - metabolism ; Signal Transduction ; Sphingolipids - metabolism ; Sphingosine ; Sphingosine - analogs &amp; derivatives ; Sphingosine - metabolism ; Sphingosine 1 Phosphate Receptor Modulators - therapeutic use ; Sphingosine-1-phosphate ; Sphingosine-1-Phosphate Receptors - drug effects ; Sphingosine-1-Phosphate Receptors - metabolism</subject><ispartof>Biomedicine &amp; pharmacotherapy, 2021-11, Vol.143, p.112197-112197, Article 112197</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-3a7c7bf7d0787d73c21d9956cfa0da061c239de60970e7236e2eff3ab1ae6b163</citedby><cites>FETCH-LOGICAL-c408t-3a7c7bf7d0787d73c21d9956cfa0da061c239de60970e7236e2eff3ab1ae6b163</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biopha.2021.112197$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34560541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shiwani, Haaris A.</creatorcontrib><creatorcontrib>Elfaki, Mohammed Y.</creatorcontrib><creatorcontrib>Memon, Danyal</creatorcontrib><creatorcontrib>Ali, Suhayb</creatorcontrib><creatorcontrib>Aziz, Abdul</creatorcontrib><creatorcontrib>Egom, Emmanuel E.</creatorcontrib><title>Updates on sphingolipids: Spotlight on retinopathy</title><title>Biomedicine &amp; pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>The sphingolipids ceramide (Cer), ceramide-1-phosphate (C1P), sphingosine (Sph), and sphingosine-1-phosphate (S1P)) are key signaling molecules that regulate many patho-biological processes. During the last decade, they have gained increasing attention since they may participate in important and numerous retinal processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Cer for instance has emerged as a key mediator of inflammation and death of neuronal and retinal pigment epithelium cells in experimental models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. S1P may have opposite biological actions, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1- phosphate may also contribute to uveitis. Furthermore, use of inhibitors that either prevent Cer increase or modulate S1P signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), have been shown to preserve neuronal viability and retinal function. Collectively, the expanding role for these sphingolipids in the modulation of vital processes in retina cell types and in their dysregulation in retinal degenerations makes them attractive therapeutic targets. •Sphingolipids are a class of diverse molecules with differing structure and function.•Cer and Sph are sphingolipids which are involved with cell death and apoptosis.•S1P and C1P are sphingolipids involved with cell proliferation.•Sphingolipid targeted drugs may be novel therapeutic options for retinopathic disease.</description><subject>Age-related macular degeneration</subject><subject>Animals</subject><subject>Ceramide</subject><subject>Ceramide-1-phosphate</subject><subject>Ceramides - metabolism</subject><subject>Fingolimod Hydrochloride - therapeutic use</subject><subject>Humans</subject><subject>Lysophospholipids - metabolism</subject><subject>Molecular Targeted Therapy</subject><subject>Photoreceptor</subject><subject>Photoreceptor Cells, Vertebrate - metabolism</subject><subject>Retina - drug effects</subject><subject>Retina - metabolism</subject><subject>Retina - pathology</subject><subject>Retinal Diseases - drug therapy</subject><subject>Retinal Diseases - metabolism</subject><subject>Retinal Diseases - pathology</subject><subject>Retinal Ganglion Cells - metabolism</subject><subject>Retinal pigment epithelium</subject><subject>Retinal Pigment Epithelium - metabolism</subject><subject>Signal Transduction</subject><subject>Sphingolipids - metabolism</subject><subject>Sphingosine</subject><subject>Sphingosine - analogs &amp; derivatives</subject><subject>Sphingosine - metabolism</subject><subject>Sphingosine 1 Phosphate Receptor Modulators - therapeutic use</subject><subject>Sphingosine-1-phosphate</subject><subject>Sphingosine-1-Phosphate Receptors - drug effects</subject><subject>Sphingosine-1-Phosphate Receptors - metabolism</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQhi0EoqXwDxDqyJJwthM7YUBCFV9SJQbobDn2pXGVxiFOkfrvaZTCyHTDPe-9uoeQawoxBSruNnHhfFvpmAGjMaWM5vKETGmeQiQA5CmZgkx5xDljE3IRwgYAUsGzczLhSSogTeiUsFVrdY9h7pt5aCvXrH3tWmfD_fyj9X3t1lU_7DrsXeNb3Vf7S3JW6jrg1XHOyOr56XPxGi3fX94Wj8vIJJD1EdfSyKKUFmQmreSGUZvnqTClBqtBUMN4blFALgEl4wIZliXXBdUoCir4jNyOd9vOf-0w9GrrgsG61g36XVAslUKkjGcDmoyo6XwIHZaq7dxWd3tFQQ221EaNttRgS422DrGbY8Ou2KL9C_3qOQAPI4CHP78ddioYh41B6zo0vbLe_d_wAxrofF4</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Shiwani, Haaris A.</creator><creator>Elfaki, Mohammed Y.</creator><creator>Memon, Danyal</creator><creator>Ali, Suhayb</creator><creator>Aziz, Abdul</creator><creator>Egom, Emmanuel E.</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Updates on sphingolipids: Spotlight on retinopathy</title><author>Shiwani, Haaris A. ; Elfaki, Mohammed Y. ; Memon, Danyal ; Ali, Suhayb ; Aziz, Abdul ; Egom, Emmanuel E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-3a7c7bf7d0787d73c21d9956cfa0da061c239de60970e7236e2eff3ab1ae6b163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age-related macular degeneration</topic><topic>Animals</topic><topic>Ceramide</topic><topic>Ceramide-1-phosphate</topic><topic>Ceramides - metabolism</topic><topic>Fingolimod Hydrochloride - therapeutic use</topic><topic>Humans</topic><topic>Lysophospholipids - metabolism</topic><topic>Molecular Targeted Therapy</topic><topic>Photoreceptor</topic><topic>Photoreceptor Cells, Vertebrate - metabolism</topic><topic>Retina - drug effects</topic><topic>Retina - metabolism</topic><topic>Retina - pathology</topic><topic>Retinal Diseases - drug therapy</topic><topic>Retinal Diseases - metabolism</topic><topic>Retinal Diseases - pathology</topic><topic>Retinal Ganglion Cells - metabolism</topic><topic>Retinal pigment epithelium</topic><topic>Retinal Pigment Epithelium - metabolism</topic><topic>Signal Transduction</topic><topic>Sphingolipids - metabolism</topic><topic>Sphingosine</topic><topic>Sphingosine - analogs &amp; derivatives</topic><topic>Sphingosine - metabolism</topic><topic>Sphingosine 1 Phosphate Receptor Modulators - therapeutic use</topic><topic>Sphingosine-1-phosphate</topic><topic>Sphingosine-1-Phosphate Receptors - drug effects</topic><topic>Sphingosine-1-Phosphate Receptors - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shiwani, Haaris A.</creatorcontrib><creatorcontrib>Elfaki, Mohammed Y.</creatorcontrib><creatorcontrib>Memon, Danyal</creatorcontrib><creatorcontrib>Ali, Suhayb</creatorcontrib><creatorcontrib>Aziz, Abdul</creatorcontrib><creatorcontrib>Egom, Emmanuel E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine &amp; pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shiwani, Haaris A.</au><au>Elfaki, Mohammed Y.</au><au>Memon, Danyal</au><au>Ali, Suhayb</au><au>Aziz, Abdul</au><au>Egom, Emmanuel E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updates on sphingolipids: Spotlight on retinopathy</atitle><jtitle>Biomedicine &amp; pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2021-11</date><risdate>2021</risdate><volume>143</volume><spage>112197</spage><epage>112197</epage><pages>112197-112197</pages><artnum>112197</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>The sphingolipids ceramide (Cer), ceramide-1-phosphate (C1P), sphingosine (Sph), and sphingosine-1-phosphate (S1P)) are key signaling molecules that regulate many patho-biological processes. During the last decade, they have gained increasing attention since they may participate in important and numerous retinal processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Cer for instance has emerged as a key mediator of inflammation and death of neuronal and retinal pigment epithelium cells in experimental models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. S1P may have opposite biological actions, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1- phosphate may also contribute to uveitis. Furthermore, use of inhibitors that either prevent Cer increase or modulate S1P signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), have been shown to preserve neuronal viability and retinal function. Collectively, the expanding role for these sphingolipids in the modulation of vital processes in retina cell types and in their dysregulation in retinal degenerations makes them attractive therapeutic targets. •Sphingolipids are a class of diverse molecules with differing structure and function.•Cer and Sph are sphingolipids which are involved with cell death and apoptosis.•S1P and C1P are sphingolipids involved with cell proliferation.•Sphingolipid targeted drugs may be novel therapeutic options for retinopathic disease.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34560541</pmid><doi>10.1016/j.biopha.2021.112197</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0753-3322
ispartof Biomedicine & pharmacotherapy, 2021-11, Vol.143, p.112197-112197, Article 112197
issn 0753-3322
1950-6007
language eng
recordid cdi_proquest_miscellaneous_2576652386
source MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Age-related macular degeneration
Animals
Ceramide
Ceramide-1-phosphate
Ceramides - metabolism
Fingolimod Hydrochloride - therapeutic use
Humans
Lysophospholipids - metabolism
Molecular Targeted Therapy
Photoreceptor
Photoreceptor Cells, Vertebrate - metabolism
Retina - drug effects
Retina - metabolism
Retina - pathology
Retinal Diseases - drug therapy
Retinal Diseases - metabolism
Retinal Diseases - pathology
Retinal Ganglion Cells - metabolism
Retinal pigment epithelium
Retinal Pigment Epithelium - metabolism
Signal Transduction
Sphingolipids - metabolism
Sphingosine
Sphingosine - analogs & derivatives
Sphingosine - metabolism
Sphingosine 1 Phosphate Receptor Modulators - therapeutic use
Sphingosine-1-phosphate
Sphingosine-1-Phosphate Receptors - drug effects
Sphingosine-1-Phosphate Receptors - metabolism
title Updates on sphingolipids: Spotlight on retinopathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T07%3A01%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updates%20on%20sphingolipids:%20Spotlight%20on%20retinopathy&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Shiwani,%20Haaris%20A.&rft.date=2021-11&rft.volume=143&rft.spage=112197&rft.epage=112197&rft.pages=112197-112197&rft.artnum=112197&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2021.112197&rft_dat=%3Cproquest_cross%3E2576652386%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2576652386&rft_id=info:pmid/34560541&rft_els_id=S0753332221009811&rfr_iscdi=true